Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Tosolini, Marie ^a,b,c,d,e,f   Algans, Christelle ^a,b   Pont, Frédéric ^a,b,c,d,e,f   Ycart, Bernard ^d,g   Fournié, Jean Jacques ^a,b,c,d,e,f  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Universitaire du Cancer de Toulouse Oncopole   (France)

^d Laboratoire d'Excellence TOUCAN   (France)

^e Programme Hospitalo Universitaire en Cancérologie CAPTOR   (France)

^f Institut Carnot Lymphome CALYM   (France)

^g UNIV GRENOBLE ALPES   (France)

Author keywords

Data mining; immune escape; lymphoma

Indexed keywords

ARTICLE; AUTOIMMUNITY; FEMALE; GENE EXPRESSION ASSAY; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; GLYCOLYSIS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; METABOLIC ACTIVITY ASSAY; MICROARRAY ANALYSIS; NONHODGKIN LYMPHOMA; RECEIVER OPERATING CHARACTERISTIC; RECEPTOR UPREGULATION; SAMPLE ENRICHMENT SCORE; SCORING SYSTEM; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 84976549815     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1188246     Document Type: Article

References (58)

1. L.Amiot, M.Onno, T.Lamy, C.Dauriac, P.Y.Le Prise, R.Fauchet, B.Drenou. Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course. Br J Haematol 1998; 100:655-63; PMID:9531330; http://dx.doi.org/10.1046/j.1365-2141.1998.00631.x
2. M.Challa-Malladi, Y.K.Lieu, O.Califano, A.B.Holmes, G.Bhagat, V.V.Murty, D.Dominguez-Sola, L.Pasqualucci, R.Dalla-Favera. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011; 20:728-40; PMID:22137796; http://dx.doi.org/10.1016/j.ccr.2011.11.006
3. L.Pasqualucci, R.Dalla-Favera. SnapShot:diffuse large B cell lymphoma. Cancer Cell 2014; 25:132-e1; PMID:24434215; http://dx.doi.org/10.1016/j.ccr.2013.12.012
4. L.Pasqualucci, H.Khiabanian, M.Fangazio, M.Vasishtha, M.Messina, A.B.Holmes, P.Ouillette, V.Trifonov, D.Rossi, F.Tabb∫ et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6:130-40; PMID:24388756; http://dx.doi.org/10.1016/j.celrep.2013.12.027
5. L.Pasqualucci, R.Dalla-Favera. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 2015; 52:67-76; PMID:25805586; http://dx.doi.org/10.1053/j.seminhematol.2015.01.005
6. M.R.Green, S.Kihira, C.L.Liu, R.V.Nair, R.Salari, A.J.Gentles, J.Irish, H.Stehr, C.Vicente-Dueñas, I.Romero-Camarero et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 2015; 112:E1116-25; PMID:25713363; http://dx.doi.org/10.1073/pnas.1501199112
7. Y.Jiang, A.Melnick. The epigenetic basis of diffuse large B-cell lymphoma. Semin Hematol 2015; 52:86-96; PMID:25805588; http://dx.doi.org/10.1053/j.seminhematol.2015.01.003
8. C.Laurent, K.Charmpi, P.Gravelle, M.Tosolini, C.Franchet, L.Ysebaert, P.Brousset, A.Bidaut, B.Ycart, J.J.Fournié. Several immune escape patterns in non-Hodgkin's lymphomas. OncoImmunology 2015; 4:e1026530; PMID:26405585; http://dx.doi.org/10.1080/2162402X.2015.1026530
9. P.Armand. Checkpoint blockade in lymphoma. Hematology Am Soc Hematol Educ Program 2015; 2015:69-73; PMID:26637703; http://dx.doi.org/0.1182/asheducation-2015.1.69
10. P.Armand. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125:3393-400; PMID:25833961; http://dx.doi.org/10.1182/blood-2015-02-567453
11. S.M.Ansell, A.M.Lesokhin, I.Borrello, A.Halwani, E.C.Scott, M.Gutierrez, S.J.Schuster, M.M.Millenson, D.Cattry, G.J.Freeman et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
12. R.Berger, R.Rotem-Yehudar, G.Slama, S.Landes, A.Kneller, M.Leiba, M.Koren-Michowitz, A.Shimoni, A.Nagler. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-51; PMID:18483370; http://dx.doi.org/10.1158/1078-0432.CCR-07-4079
13. J.R.Westin, F.Chu, M.Zhang, L.E.Fayad, L.W.Kwak, N.Fowler, J.Romaguera, F.Hagemeister, M.Fanale, F.Samaniego et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma:a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx.doi.org/10.1016/S1470-2045(13)70551-5
14. A.J.Gentles, A.M.Newman, C.L.Liu, S.V.Bratman, W.Feng, D.Kim, V.S.Nair, Y.Xu, A.Khuong, C.D.Hoang et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21:938-45; PMID:26193342; http://dx.doi.org/10.1038/nm.3909
15. K.Hebestreit, S.Grottrup, D.Emden, J.Veerkamp, C.Ruckert, H.U.Klein, C.Müller-Tidow, M.Dugas. Leukemia gene atlas–a public platform for integrative exploration of genome-wide molecular data. PLoS One 2012; 7:e39148; PMID:22720055; http://dx.doi.org/10.1371/journal.pone.0039148
16. H.K.Lee, A.K.Hsu, J.Sajdak, J.Qin, P.Pavlidis. Coexpression analysis of human genes across many microarray data sets. Genome Res 2004; 14:1085-94; PMID:15173114; http://dx.doi.org/10.1101/gr.1910904
17. H.Mizuno, Y.Nakanishi, N.Ishii, A.Sarai, K.Kitada. A signature-based method for indexing cell cycle phase distribution from microarray profiles. BMC Genomics 2009; 10:137; PMID:19331659; http://dx.doi.org/10.1186/1471-2164-10-137
18. A.M.Newman, C.L.Liu, M.R.Green, A.J.Gentles, W.Feng, Y.Xu, C.D.Hoang, M.Diehn, A.A.Alizadeh. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12:453-7; PMID:25822800; http://dx.doi.org/10.1038/nmeth.3337
19. A.Subramanian, P.Tamayo, V.K.Mootha, S.Mukherjee, B.L.Ebert, M.A.Gillette, A.Paulovich, S.L.Pomeroy, T.R.Golub, E.S.Lander et al. Gene set enrichment analysis:A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
20. B.Ycart, F.Pont, J.J.Fournie. Curbing false discovery rates in interpretation of genome-wide expression profiles. J Biomed Inform 2014; 47:58-61; PMID:24060601; http://dx.doi.org/10.1016/j.jbi.2013.09.004
21. D.A.Barbie, P.Tamayo, J.S.Boehm, S.Y.Kim, S.E.Moody, I.F.Dunn, A.C.Schinzel, P.Sandy, E.Meylan, C.Scholl et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-12; PMID:19847166; http://dx.doi.org/10.1038/nature08460
22. R.G.Verhaak, K.A.Hoadley, E.Purdom, V.Wang, Y.Qi, M.D.Wilkerson, C.R.Miller, L.Ding, T.Golub, J.P.Mesirov et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98-110; PMID:20129251; http://dx.doi.org/10.1016/j.ccr.2009.12.020
23. K.Yoshihara, M.Shahmoradgoli, E.Martinez, R.Vegesna, H.Kim, W.Torres-Garcia, V.Treviño, H.Shen, P.W.Laird, D.A.Levine et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4:2612; PMID:24113773; http://dx.doi.org/10.1038/ncomms3612
24. G.Gundem, N.Lopez-Bigas. Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. Genome Med 2012; 4:28; PMID:22458606; http://dx.doi.org/10.1186/gm327
25. P.G.Ferreira, P.Jares, D.Rico, G.Gomez-Lopez, A.Martinez-Trillos, N.Villamor, S.Ecker, A.González-Pérez, D.G.Knowles, J.Monlong et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res 2014; 24:212-26; PMID:24265505; http://dx.doi.org/10.1101/gr.152132.112
26. J.Isensee, H.Witt, R.Pregla, R.Hetzer, V.Regitz-Zagrosek, P.R.Noppinger. Sexually dimorphic gene expression in the heart of mice and men. J Mol Med (Berl) 2008; 86:61-74; PMID:17646949; http://dx.doi.org/10.1007/s00109-007-0240-z
27. A.A.Alizadeh, M.B.Eisen, R.E.Davis, C.Ma, I.S.Lossos, A.Rosenwald, J.C.Boldrick, H.Sabet, T.Tran, X.Yu et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11; PMID:10676951; http://dx.doi.org/10.1038/35000501
28. A.Rosenwald, G.Wright, K.Leroy, X.Yu, P.Gaulard, R.D.Gascoyne, W.C.Chan, T.Zhao, C.Haioun, T.C.Greiner et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851-62; PMID:12975453; http://dx.doi.org/10.1084/jem.20031074
29. G.Wright, B.Tan, A.Rosenwald, E.H.Hurt, A.Wiestner, L.M.Staudt. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100:9991-6; PMID:12900505; http://dx.doi.org/10.1073/pnas.1732008100
30. H.C.Kluin-Nelemans, G.C.Beverstock, P.Mollevanger, H.W.Wessels, E.Hoogendoorn, R.Willemze et al. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen. Blood 1994; 84:3134-41; PMID:7524766
31. J.A.Ferry. Burkitt's lymphoma:clinicopathologic features and differential diagnosis. Oncologist 2006; 11:375-83; PMID:16614233; http://dx.doi.org/10.1634/theoncologist.11-4-375
32. G.Lenz, G.Wright, S.S.Dave, W.Xiao, J.Powell, H.Zhao, W.Xu, B.Tan, N.Goldschmidt, J.Iqbal et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359:2313-23; PMID:19038878; http://dx.doi.org/10.1056/NEJMoa0802885
33. R.Schmitz, R.M.Young, M.Ceribelli, S.Jhavar, W.Xiao, M.Zhang, G.Wright, A.L.Shaffer, D.J.Hodson, E.Buras et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490:116-20; PMID:22885699; http://dx.doi.org/10.1038/nature11378
34. M.Meignan. Quantitative FDG-PET:a new biomarker in PMBCL. Blood 2015; 126:924-6; PMID:26294712; http://dx.doi.org/10.1182/blood-2015-07-653386
35. X.Wu, H.Pertovaara, P.Korkola, M.Vornanen, H.Eskola, P.L.Kellokumpu-Lehtinen. Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma. Leuk Lymphoma 2012; 53:400-5; PMID:21913807; http://dx.doi.org/10.3109/10428194.2011.622420
36. M.Xie, K.Wu, Y.Liu, Q.Jiang, Y.Xie. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma:a meta-analysis with 702 participants. Med Oncol 2015; 32:446; PMID:25511321; http://dx.doi.org/10.1007/s12032-014-0446-1
37. S.S.Dave, G.Wright, B.Tan, A.Rosenwald, R.D.Gascoyne, W.C.Chan, R.I.Fisher, R.M.Braziel, L.M.Rimsza, T.M.Grogan et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159-69; PMID:15548776; http://dx.doi.org/10.1056/NEJMoa041869
38. N.Guillaume, J.P.Marolleau. Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies. Leuk Res 2013; 37:473-7; PMID:23347904; http://dx.doi.org/10.1016/j.leukres.2012.12.021
39. L.Ysebaert, J.J.Fournie. Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 2011; 52:1404-6; PMID:21699388; http://dx.doi.org/10.3109/10428194.2011.568078
40. C.Germain, T.Guillaudeux, E.D.Galsgaard, C.Hervouet, N.Tekaya, A.S.Gallouet, J.Fassy, F.Bihl, G.Poupon, A.Lazzari et al. Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. Oncoimmunology 2015; 4:e1026503; PMID:26405582; http://dx.doi.org/10.1080/2162402X.2015.1026503
41. J.M.God, D.Zhao, C.A.Cameron, S.Amria, J.R.Bethard, A.Haque. Disruption of HLA class II antigen presentation in Burkitt lymphoma:implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology 2014; 142:492-505; PMID:24628049; http://dx.doi.org/10.1111/imm.12281
42. S.S.Neelapu, L.W.Kwak, C.B.Kobrin, C.W.Reynolds, J.E.Janik, K.Dunleavy, T.White, L.Harvey, R.Pennington, M.Stetler-Stevenson et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005; 11:986-91; PMID:16116429; http://dx.doi.org/10.1038/nm1290
43. L.Wang, J.Qian, Y.Lu, H.Li, H.Bao, D.He, Z.Liu, Y.Zheng, J.He, Y.Li et al. Immune evasion of mantle cell lymphoma:expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 2013; 98:1458-66; PMID:23508008; http://dx.doi.org/10.3324/haematol.2012.071340
44. L.Xerri, B.Chetaille, N.Serriari, C.Attias, Y.Guillaume, C.Arnoulet, D.Olive. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 39:1050-8; PMID:18479731; http://dx.doi.org/10.1016/j.humpath.2007.11.012
45. C.A.Dasanu, B.Bockorny, J.Grabska, I.Codreanu. Prevalence and Pattern of Autoimmune Conditions in Patients with Marginal Zone Lymphoma:A Single Institution Experience. Conn Med 2015; 79:197-200; PMID:26259295
46. D.Mittal, M.M.Gubin, R.D.Schreiber, M.J.Smyth. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 2014; 27:16-25; PMID:24531241; http://dx.doi.org/10.1016/j.coi.2014.01.004
47. R.G.Verhaak, P.Tamayo, J.Y.Yang, D.Hubbard, H.Zhang, C.J.Creighton, S.Fereday, M.Lawrence, S.L.Carter, C.H.Mermel et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013; 123:517-25; PMID:23257362; http://dx.doi.org/10.1172/JCI65833
48. B.Ycart, K.Charmpi, S.Rousseaux, J.J.Fournie. Large scale statistical analysis of GEO datasets. Gene Technol 2014; 3:1-9; http://dx.doi.org/10.4172/2329-6682.1000113
49. G.P.Dunn, L.J.Old, R.D.Schreiber. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104803
50. R.Edgar, M.Domrachev, A.E.Lash. Gene Expression Omnibus:NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207-10; PMID:11752295; http://dx.doi.org/10.1093/nar/30.1.207
51. M.A.Harris, J.Clark, A.Ireland, J.Lomax, M.Ashburner, R.Foulger, K.Eilbeck, S.Lewis, B.Marshall, C.Mungall et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004; 32:D258-61; PMID:14681407; http://dx.doi.org/10.1093/nar/gkh066
52. A.Liberzon, A.Subramanian, R.Pinchback, H.Thorvaldsdottir, P.Tamayo, J.P.Mesirov. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27:1739-40; PMID:21546393; http://dx.doi.org/10.1093/bioinformatics/btr260
53. A.Tsodikov, A.Szabo, D.Jones. Adjustments and measures of differential expression for microarray data. Bioinformatics 2002; 18:251-60; PMID:11847073; http://dx.doi.org/10.1093/bioinformatics/18.2.251
54. P.Warnat, R.Eils, B.Brors. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. Bmc Bio Informatics 2005; 6:265; PMID:16271137; http://dx.doi.org/10.1186/1471-2105-6-265
55. K.Charmpi, B.Ycart. Weighted Kolmogorov Smirnov testing:an alternative for Gene Set Enrichment Analysis. Statistical Applications Genetics Mol Biol 2015; 14:279-93; PMID:26030794; http://dx.doi.org/10.1515/sagmb-2014-0077
56. X.Cui, G.A.Churchill. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003; 4:210; PMID:12702200; http://dx.doi.org/10.1186/gb-2003-4-4-210
57. R.A.Irizarry, C.Wang, Y.Zhou, T.P.Speed. Gene set enrichment analysis made simple. Stat Methods Med Res 2009; 18:565-75; PMID:20048385; http://dx.doi.org/10.1177/0962280209351908
58. V.K.Mootha, C.M.Lindgren, K.F.Eriksson, A.Subramanian, S.Sihag, J.Lehar, P.Puigserver, E.Carlsson, M.Ridderstråle, E.Laurila et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267-73; PMID:12808457; http://dx.doi.org/10.1038/ng1180